EMA (EU)
GUIDANCE FINAL
Concept paper on the revision of the guideline on pharmaceutical fixed combination products (EMA/CVMP/83804/2005-Rev.1)
Published: 7/24/2026Detected: 7/24/2026
Summary preview
Clarifies and expands the EMA/CVMP guidance for evaluating pharmaceutical fixed combination veterinary medicinal products, aiming to improve consistency of efficacy, safety, and residues documentation expectations under…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
pediatrics
respiratory
manufacturing
quality
clinical
safety
labeling
#veterinary medicinal products
#fixed combination products
#pharmaceutical fixed combinations
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026